By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Antiviral combinations > Viekira xr > Dasabuvir / Ombitasvir / Paritaprevir / Ritonavir Dosage
Antiviral combinations
https://themeditary.com/dosage-information/dasabuvir-ombitasvir-paritaprevir-ritonavir-dosage-4430.html

Dasabuvir / Ombitasvir / Paritaprevir / Ritonavir Dosage

Drug Detail:Viekira xr (Dasabuvir, ombitasvir, paritaprevir, and ritonavir [ da-sab-ue-vir, om-bit-as-vir, par-i-tap-re-vir, and-rye-ton-a-vir ])

Drug Class: Antiviral combinations

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Chronic Hepatitis C

Viekira Pak:

  • Dasabuvir: 250 mg orally twice a day (morning and evening)
  • Ombitasvir/paritaprevir/ritonavir fixed-dose combination tablet: 2 tablets orally once a day (in the morning)

Extended-release tablets (fixed-dose combination): 3 tablets orally once a day

Recommended Regimen and Duration of Therapy:
  • Genotype 1a, without cirrhosis: Viekira Pak plus ribavirin OR extended-release tablets plus ribavirin for 12 weeks
  • Genotype 1a, with compensated cirrhosis (Child-Pugh A): Viekira Pak plus ribavirin OR extended-release tablets plus ribavirin for 24 weeks
  • For some patients based on prior treatment history: May consider Viekira Pak plus ribavirin OR extended-release tablets plus ribavirin for 12 weeks
  • Genotype 1b, with or without compensated cirrhosis (Child-Pugh A): Viekira Pak OR extended-release tablets for 12 weeks
  • Liver transplant recipients with normal liver function and mild fibrosis (Metavir fibrosis score 2 or lower), regardless of HCV genotype 1 subtype: Viekira Pak plus ribavirin OR extended-release tablets plus ribavirin for 24 weeks

Comments:
  • Recommended for therapy-naive or interferon-experienced patients, including those with HCV/HIV-1 coinfection
  • The dosing recommendations for genotype 1a should be followed for patients with unknown genotype 1 subtype or with mixed genotype 1 infection.
  • The manufacturer product information should be consulted for ribavirin dosing recommendations (if applicable), regarding dosing of concomitant HIV-1 antiviral drugs in HCV/HIV-1-coinfected patients, and regarding use with calcineurin inhibitors in liver transplant recipients.
  • The manufacturer product information for ribavirin should be consulted regarding dose adjustments (if applicable).

Uses: For the treatment of chronic HCV infection
  • In genotype 1b-infected patients without cirrhosis or with compensated cirrhosis
  • In combination with ribavirin: In genotype 1a-infected patients without cirrhosis or with compensated cirrhosis

Renal Dose Adjustments

Mild, moderate, or severe renal dysfunction: No adjustment recommended.

Comments:

  • If required, the manufacturer product information for ribavirin should be consulted regarding use in patients with renal dysfunction.

Liver Dose Adjustments

Mild liver dysfunction (Child-Pugh A): No adjustment recommended.
Moderate to severe liver dysfunction (Child-Pugh B and C): Contraindicated

Precautions

US BOXED WARNING:

  • RISK OF HBV REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV: All patients should be tested for evidence of current/prior HBV infection before starting this product. HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death. HCV/HBV-coinfected patients should be monitored for hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.

CONTRAINDICATIONS:
  • If used with ribavirin: Contraindications to ribavirin
  • Moderate to severe liver dysfunction (Child-Pugh B and C)
  • Coadministration with drugs highly dependent on CYP450 3A for clearance and for which elevated plasma levels are associated with serious and/or life-threatening events, including alfuzosin, ranolazine, dronedarone, colchicine (in patients with renal and/or liver dysfunction), lurasidone, pimozide, ergotamine, dihydroergotamine, methylergonovine, ethinyl estradiol-containing products (e.g., combined oral contraceptives), cisapride, lovastatin, simvastatin, atorvastatin, everolimus, sirolimus, tacrolimus, lomitapide, efavirenz, oral midazolam, triazolam, sildenafil (for treatment of pulmonary arterial hypertension)
  • Coadministration with drugs that are moderate or strong inducers of CYP450 3A and strong inducers of CYP450 2C8 and may lead to reduced efficacy of this product, including carbamazepine, phenytoin, phenobarbital, apalutamide, rifampin, St. John's wort
  • Coadministration with drugs that are strong CYP450 2C8 inhibitors and may increase dasabuvir plasma levels and risk of QT prolongation, including gemfibrozil
  • Known hypersensitivity to ritonavir (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome)

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

No adjustment recommended.

Other Comments

Administration advice:

  • Before starting this product, test all patients for evidence of current/prior HBV infection; measure hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc).
  • Before starting this product, assess for laboratory and clinical evidence of hepatic decompensation.
  • Administer Viekira Pak with a meal, without regard to fat or calorie content.
  • Must administer extended-release tablets with a meal; reduced virologic response and possible resistance development may occur if administered under fasting conditions.
  • Swallow extended-release tablets whole; do not split, crush, or chew (may compromise performance, efficacy, and/or safety of product).
  • For optimal release of dasabuvir, do not consume alcohol within 4 hours of taking the extended-release tablets.

Storage requirements:
  • Store at or below 30C (86F).

General:
  • Viekira Pak is ombitasvir/paritaprevir/ritonavir fixed-dose combination tablets copackaged with dasabuvir tablets; each fixed-dose combination tablet contains ombitasvir 12.5 mg, paritaprevir 75 mg, and ritonavir 50 mg.
  • Each fixed-dose combination extended-release tablet contains dasabuvir 200 mg, ombitasvir 8.33 mg, paritaprevir 50 mg, and ritonavir 33.33 mg.
  • The manufacturer product information for ribavirin should be consulted for additional information (if applicable).

Monitoring:
  • Hepatic: For laboratory and clinical evidence of hepatic decompensation (before starting therapy); for clinical signs/symptoms of hepatic decompensation in cirrhosis patients; hepatic laboratory tests, including direct bilirubin, in cirrhosis patients (at baseline, during first 4 weeks of therapy, then as clinically indicated); ALT (if increases above baseline levels)

Patient advice:
  • Read the US FDA-approved patient information (Medication Guide) for this product and review the Medication Guide for ribavirin, if applicable.
  • Watch for signs of liver inflammation/failure (e.g., early signs: fatigue, weakness, lack of appetite, nausea and vomiting; later signs: jaundice, onset of confusion, abdominal swelling, discolored feces); consult healthcare provider immediately if these symptoms develop.
  • Take extreme care to avoid pregnancy during use of this product with ribavirin and within 6 months of stopping ribavirin in female patients and female partners of male patients; inform healthcare provider immediately in the event of pregnancy.
  • Avoid missing doses and complete the entire course of therapy; do not remove tablets from daily dose pack until you are ready to take them.

Frequently asked questions

  • What are the new drugs for the treatment of hepatitis C?
Share this Article
Latest News
Medical News

Does daydreaming make you smarter?

Jul 06, 2025
Alzheimer's disease: Do breast cancer survivors have a lower risk?
Dementia: Novel brain scan may predict age-related disease
Weight loss: How do low-fat vegan and Mediterranean diets compare?
Diabetes: Swapping diet soda for water boosts chances of remission
Prediabetes: Just over 2 hours of exercise a week could reverse it
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by